Clinical Efficacy of Baloxavir Marboxil in the Treatment of Seasonal Influenza in Adult Patients: A Prospective Observational Study
Authors Yoshino Y, Kitazawa T, Ota Y
Received 22 July 2020
Accepted for publication 7 September 2020
Published 1 October 2020 Volume 2020:13 Pages 735—741
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Scott Fraser
Yusuke Yoshino,1 Takatoshi Kitazawa,1 Yasuo Ota2
1Department of Internal Medicine, Teikyo University School of Medicine, Itabashi, Tokyo, Japan; 2Department of Internal Medicine, National Hospital Organization Higashi Saitama Hospital, Hasuda, Saitama, Japan
Correspondence: Yusuke Yoshino Department of Internal Medicine
Teikyo University School of Medicine, 2-11-1 Kaga, Itabashi-ku 173-8605, Tokyo, Japan
Tel +81 3 3964 1211 (Ext 7731)
Fax +81 3 3579 6310
Purpose: Baloxavir marboxil, a recently developed antiviral drug, has been used to treat influenza in some countries including Japan. The aim of this study was to determine the clinical efficacy of the drug, which currently remains unclear.
Patients and Methods: Overall, 43 adult patients with seasonal influenza who visited the outpatient clinic of Teikyo University Hospital in Tokyo during the winter of 2018– 2019 were enrolled. Of them, 14, 13, and 16 were prescribed baloxavir marboxil (40 or 80 mg once), oseltamivir (75 mg twice daily for 5 days), and laninamivir (40 mg once), respectively. A questionnaire was used to collect data about symptoms, and the Medical Outcome Study 8-Items Short Form Health Survey was employed to examine health-related quality-of-life (HRQOL) before and 7 days after admission. The main study endpoints included time to defervescence and the extent of improvement in HRQOL after treatment initiation. The data were analyzed with Welch’s t-test and Fisher’s exact test using StatFlex version 6.
Results: No significant differences in clinical background characteristics were observed among the patients. The mean time to defervescence in the baloxavir group (median [interquartile range]; 1.0 [1.0– 2.0] days) was significantly shorter than that in the laninamivir group (2.0 [1.5– 3.5] days; p=0.0322). No significant differences in mean time to defervescence, change in HRQOL, and time for resolution of other symptoms were observed between the groups.
Conclusion: The results suggest that baloxavir marboxil has a better antipyretic effect than oseltamivir and laninamivir. Moreover, baloxavir marboxil might be clinically more valuable than the other two drugs owing to higher medication adherence among patients.
Keywords: seasonal influenza, baloxavir marboxil, clinical efficacies, health-related quality-of-life
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]